Rigel Pharmaceuticals (NASDAQ:RIGL) Raised to “Hold” at Zacks Research

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks reports.

RIGL has been the subject of several other research reports. Cantor Fitzgerald upped their price objective on shares of Rigel Pharmaceuticals from $43.00 to $47.00 and gave the company a “neutral” rating in a research note on Friday, November 6th. Piper Sandler reiterated a “neutral” rating and issued a $49.00 price objective (up from $40.00) on shares of Rigel Pharmaceuticals in a report on Monday, August 17th. HC Wainwright reissued a “buy” rating and issued a $85.00 target price on shares of Rigel Pharmaceuticals in a research note on Monday, October 19th. Weiss Ratings cut Rigel Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, November 9th. Finally, Citigroup boosted their target price on Rigel Pharmaceuticals from $83.00 to $86.00 and gave the stock a “buy” rating in a report on Monday, November 9th. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Rigel Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $66.75.

Read Our Latest Analysis on Rigel Pharmaceuticals

Rigel Pharmaceuticals Stock Down 2.7%

Shares of Rigel Pharmaceuticals stock traded down $1.23 during trading hours on Thursday, reaching $44.46. 151,588 shares of the company’s stock were exchanged, compared to its average volume of 261,596. Rigel Pharmaceuticals has a 1 year low of $24.95 and a 1 year high of $52.60. The company has a market capitalization of $837.18 million, a P/E ratio of 2.87 and a beta of 1.28. The business has a fifty day moving average of $47.44 and a two-hundred day moving average of $37.64.

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.27). The business had revenue of $80.89 million during the quarter, compared to analyst estimates of $80.00 million. Rigel Pharmaceuticals had a net margin of 106.59% and a return on equity of 14.89%. As a group, research analysts predict that Rigel Pharmaceuticals will post 2.97 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Signature Equity Partners LLC acquired a new position in shares of Rigel Pharmaceuticals during the 3rd quarter valued at about $27,000. Signaturefd LLC increased its position in Rigel Pharmaceuticals by 180.0% during the third quarter. Signaturefd LLC now owns 826 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 531 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Rigel Pharmaceuticals during the third quarter worth about $46,000. Integrated Wealth Concepts LLC acquired a new stake in Rigel Pharmaceuticals during the second quarter worth about $38,000. Finally, Allworth Financial LP increased its position in Rigel Pharmaceuticals by 103.7% during the third quarter. Allworth Financial LP now owns 982 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 66.23% of the company’s stock.

About Rigel Pharmaceuticals

(Get Free Report)

Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for people with serious hematologic disorders and cancers. Founded in 1996 and based in South San Francisco, California, the company has focused on treatments that target biological pathways involved in disease. Rigel’s marketed products include Tavalisse (fostamatinib), an oral treatment for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment, and Rezlidhia (olutasidenib), an oral therapy for certain adults with relapsed or refractory acute myeloid leukemia containing an IDH1 mutation.

See Also

Analyst Recommendations for Rigel Pharmaceuticals (NASDAQ:RIGL)

Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.